Search

Your search keyword '"Eltahir, Zakaria"' showing total 25 results
Start Over Author "Eltahir, Zakaria" Publication Year Range Last 50 years
25 results on '"Eltahir, Zakaria"'

2. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Author

Vlachogiannis, Georgios, Hedayat, Somaieh, Vatsiou, Alexandra, Jamin, Yann, Fernández-Mateos, Javier, Khan, Khurum, Lampis, Andrea, Eason, Katherine, Huntingford, Ian, Burke, Rosemary, Rata, Mihaela, Koh, Dow-Mu, Tunariu, Nina, Collins, David, Hulkki-Wilson, Sanna, Ragulan, Chanthirika, Spiteri, Inmaculada, Moorcraft, Sing Yu, Chau, Ian, Rao, Sheela, Watkins, David, Fotiadis, Nicos, Bali, Maria, Darvish-Damavandi, Mahnaz, Lote, Hazel, Eltahir, Zakaria, Smyth, Elizabeth C., Begum, Ruwaida, Clarke, Paul A., Hahne, Jens C., Dowsett, Mitchell, de Bono, Johann, Workman, Paul, Sadanandam, Anguraj, Fassan, Matteo, Sansom, Owen J., Eccles, Suzanne, Starling, Naureen, Braconi, Chiara, Sottoriva, Andrea, Robinson, Simon P., Cunningham, David, and Valeri, Nicola

Published
2018

3. MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma

Author

Lampis, Andrea, Carotenuto, Pietro, Vlachogiannis, Georgios, Cascione, Luciano, Hedayat, Somaieh, Burke, Rosemary, Clarke, Paul, Bosma, Else, Simbolo, Michele, Scarpa, Aldo, Yu, Sijia, Cole, Rebecca, Smyth, Elizabeth, Mateos, Javier Fernández, Begum, Ruwaida, Hezelova, Blanka, Eltahir, Zakaria, Wotherspoon, Andrew, Fotiadis, Nicos, Bali, Maria Antonietta, Nepal, Chirag, Khan, Khurum, Stubbs, Mark, Hahne, Jens C., Gasparini, Pierluigi, Guzzardo, Vincenza, Croce, Carlo M., Eccles, Suzanne, Fassan, Matteo, Cunningham, David, Andersen, Jesper B., Workman, Paul, Valeri, Nicola, and Braconi, Chiara

Published
2018
Full Text
View/download PDF

5. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial

Author

Smyth, Elizabeth C., Wotherspoon, Andrew, Peckitt, Clare, Gonzalez, David, Hulkki-Wilson, Sanna, Eltahir, Zakaria, Fassan, Matteo, Rugge, Massimo, Valeri, Nicola, Okines, Alicia, Hewish, Madeleine, Allum, William, Stenning, Sally, Nankivell, Matthew, Langley, Ruth, and Cunningham, David

Published
2017
Full Text
View/download PDF

8. The genomic landscape of oesophagogastric junctional adenocarcinoma

Author

Chong, Irene Y, Cunningham, David, Barber, Louise J, Campbell, James, Chen, Lina, Kozarewa, Iwanka, Fenwick, Kerry, Assiotis, Ioannis, Guettler, Sebastian, Garcia-Murillas, Isaac, Awan, Saima, Lambros, Maryou, Starling, Naureen, Wotherspoon, Andrew, Stamp, Gordon, Gonzalez-de-Castro, David, Benson, Martin, Chau, Ian, Hulkki, Sanna, Nohadani, Mahrokh, Eltahir, Zakaria, Lemnrau, Alina, Orr, Nicholas, Rao, Sheela, Lord, Christopher J, and Ashworth, Alan

Published
2013
Full Text
View/download PDF

9. Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study

Author

Khan, Khurum, Rata, Mihaela, Cunningham, David, Koh, Dow-Mu, Tunariu, Nina, Hahne, Jens C., Vlachogiannis, George, Hedayat, Somaieh, Marchetti, Silvia, Lampis, Andrea, Damavandi, Mahnaz Darvish, Lote, Hazel, Rana, Isma, Williams, Anja, Eccles, Suzanne A., Fontana, Elisa, Collins, David, Eltahir, Zakaria, Rao, Sheela, Watkins, David, Starling, Naureen, Thomas, Jan, Kalaitzaki, Eleftheria, Fotiadis, Nicos, Begum, Ruwaida, Bali, Maria, Rugge, Massimo, Temple, Eleanor, Fassan, Matteo, Chau, Ian, Braconi, Chiara, and Valeri, Nicola

Subjects
Adult, Male, liquid biopsy, Colon, anti-angiogenic treatment, DCE-MRI, Pyridines, Phenylurea Compounds, colorectal cancer, cancer therapeutics, regorafenib, Kaplan-Meier Estimate, Middle Aged, Magnetic Resonance Imaging, Treatment Outcome, Humans, Female, Prospective Studies, Colorectal Neoplasms, Biomarkers, Aged
Abstract

Objective: Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection.\ud \ud Design: Patients with RAS mutant mCRC with biopsiable metastases were enrolled in this phase II trial. Dynamic contrast-enhanced (DCE) MRI was acquired pretreatment and at day 15 post-treatment. Median values of volume transfer constant (Ktrans), enhancing fraction (EF) and their product KEF (summarised median values of Ktrans× EF) were generated. Circulating tumour (ct) DNA was collected monthly until progressive disease and tested for clonal RAS mutations by digital-droplet PCR. Tumour vasculature (CD-31) was scored by immunohistochemistry on 70 sequential tissue biopsies.\ud \ud Results: Twenty-seven patients with paired DCE-MRI scans were analysed. Median KEF decrease was 58.2%. Of the 23 patients with outcome data, >70% drop in KEF (6/23) was associated with higher disease control rate (p=0.048) measured by RECIST V. 1.1 at 2 months, improved progression-free survival (PFS) (HR 0.16 (95% CI 0.04 to 0.72), p=0.02), 4-month PFS (66.7% vs 23.5%) and overall survival (OS) (HR 0.08 (95% CI 0.01 to 0.63), p=0.02). KEF drop correlated with CD-31 reduction in sequential tissue biopsies (p=0.04). RAS mutant clones decay in ctDNA after 8 weeks of treatment was associated with better PFS (HR 0.21 (95% CI 0.06 to 0.71), p=0.01) and OS (HR 0.28 (95% CI 0.07–1.04), p=0.06).\ud \ud Conclusions: Combining DCE-MRI and ctDNA predicts duration of anti-angiogenic response to regorafenib and may improve patient management with potential health/economic implications.

Published
2017

10. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer

Author

Sclafani, Francesco, Chau, Ian, Cunningham, David, Hahne, Jens C., Vlachogiannis, George, Eltahir, Zakaria, Lampis, Andrea, Braconi, Chiara, Kalaitzaki, Eleftheria, De Castro, David Gonzalez, Wotherspoon, Andrew, Capdevila Castillón, Jaume, Glimelius, Bengt, Tarazona, Noelia, Begum, Ruwaida, Lote, Hazel, Hulkki Wilson, Sanna, Mentrasti, Giulia, Brown, Gina, Tait, Diana, Oates, Jacqueline, Valeri, Nicola, and Universitat Autònoma de Barcelona

Subjects
neoplasms, digestive system diseases
Abstract

There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX ± cetuximab in a randomised phase II trial. KRAS mutation in G12D, G12V or G13D was detected in the ctDNA of 43% and 35% of patients with tumours that were mutant and wild-type for these hotspot mutations, respectively, according to standard PCR-based analyses on tissue. The detection rate in the ctDNA of 10 patients with less common mutations was 50%. In 26 cases ctDNA analysis revealed KRAS mutations that were not previously found in tissue. Twenty-two of these (84.6%) were detected following repeat tissue testing by ddPCR. Overall, the ctDNA detection rate in the KRAS mutant population was 66%. Detection of KRAS mutation in ctDNA failed to predict prognosis or refine patient selection for cetuximab. While this study confirms the feasibility of ctDNA analysis in LARC and the high sensitivity of ddPCR, larger series are needed to better address the role of ctDNA as a prognostic or predictive tool in this setting

Published
2018

11. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer

Author

Sclafani, Francesco, Chau, Ian, Cunningham, David, Hahne, Jens C., Vlachogiannis, George, Eltahir, Zakaria, Lampis, Andrea, Braconi, Chiara, Kalaitzaki, Eleftheria, De Castro, David Gonzalez, Wotherspoon, Andrew, Capdevila, Jaume, Glimelius, Bengt, Tarazona, Noelia, Begum, Ruwaida, Lote, Hazel, Hulkki Wilson, Sanna, Mentrasti, Giulia, Brown, Gina, Tait, Diana, Oates, Jacqueline, and Valeri, Nicola

Subjects
Male, Proto-Oncogene Proteins B-raf, Organoplatinum Compounds, Science, Cetuximab, Article, Circulating Tumor DNA, Proto-Oncogene Proteins p21(ras), SDG 3 - Good Health and Well-being, Antineoplastic Combined Chemotherapy Protocols, Journal Article, Humans, neoplasms, Capecitabine, Digestive System Surgical Procedures, Aged, Rectal Neoplasms, Chemoradiotherapy, Adjuvant, Middle Aged, Prognosis, digestive system diseases, Oxaliplatin, Treatment Outcome, Mutation, Medicine, Female
Abstract

There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX ± cetuximab in a randomised phase II trial. KRAS mutation in G12D, G12V or G13D was detected in the ctDNA of 43% and 35% of patients with tumours that were mutant and wild-type for these hotspot mutations, respectively, according to standard PCR-based analyses on tissue. The detection rate in the ctDNA of 10 patients with less common mutations was 50%. In 26 cases ctDNA analysis revealed KRAS mutations that were not previously found in tissue. Twenty-two of these (84.6%) were detected following repeat tissue testing by ddPCR. Overall, the ctDNA detection rate in the KRAS mutant population was 66%. Detection of KRAS mutation in ctDNA failed to predict prognosis or refine patient selection for cetuximab. While this study confirms the feasibility of ctDNA analysis in LARC and the high sensitivity of ddPCR, larger series are needed to better address the role of ctDNA as a prognostic or predictive tool in this setting.

Published
2017

12. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer

Author

Sclafani, Francesco, primary, Chau, Ian, additional, Cunningham, David, additional, Hahne, Jens C., additional, Vlachogiannis, George, additional, Eltahir, Zakaria, additional, Lampis, Andrea, additional, Braconi, Chiara, additional, Kalaitzaki, Eleftheria, additional, De Castro, David Gonzalez, additional, Wotherspoon, Andrew, additional, Capdevila, Jaume, additional, Glimelius, Bengt, additional, Tarazona, Noelia, additional, Begum, Ruwaida, additional, Lote, Hazel, additional, Hulkki Wilson, Sanna, additional, Mentrasti, Giulia, additional, Brown, Gina, additional, Tait, Diana, additional, Oates, Jacqueline, additional, and Valeri, Nicola, additional

Published
2018
Full Text
View/download PDF

14. Abstract 422: Lymph node metastasis evolution drives immune evasion and targeted therapy resistance in gastro-esophageal adenocarcinomas (GEAs)

Author

Davies, Matthew N., primary, Barber, Louise J., additional, Spain, Georgia, additional, Lopes, Filipa, additional, Loga, Katharina von, additional, Griffiths, Beatrice, additional, Woolston, Andrew, additional, Alpar, Donat, additional, Gomez, Marta, additional, Lipinski, Kamil A., additional, Fenwick, Kerry, additional, Eltahir, Zakaria, additional, Lise, Stefano, additional, Agoston, Emese I., additional, Harsanyi, Laszlo, additional, Marais, Richard, additional, Wotherspoon, Andrew, additional, Szasz, A, additional, Springer, Caroline, additional, and Gerlinger, Marco, additional

Published
2017
Full Text
View/download PDF

15. Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment

Author

Moorcraft, Sing Y., primary, Jones, Thomas, additional, Walker, Brian A., additional, Ladas, George, additional, Kalaitzaki, Eleftheria, additional, Yuan, Lina, additional, Begum, Ruwaida, additional, Eltahir, Zakaria, additional, Wotherspoon, Andrew, additional, Montero-Fernandez, Angeles, additional, Teixeira Mendes, Larissa S., additional, Gonzalez de Castro, David, additional, Wilson, Sanna Hulkki, additional, Proszek, Paula, additional, To, Ye M., additional, Hawkes, Eliza, additional, Roy, Amitesh, additional, Cunningham, David, additional, Rao, Sheela, additional, Watkins, David, additional, Starling, Naureen, additional, Bowcock, Anne M., additional, and Chau, Ian, additional

Published
2017
Full Text
View/download PDF

16. Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients

Author

Sclafani, Francesco, Chau, Ian, Cunningham, David, Lampis, Andrea, Hahne, Jens Claus, Ghidini, Michele, Lote, Hazel, Zito, Domenico, Tabernero, Josep, Glimelius, Bengt, Cervantes, Andres, Begum, Ruwaida, De Castro, David Gonzalez, Wilson, Sanna Hulkki, Peckitt, Clare, Eltahir, Zakaria, Wotherspoon, Andrew, Tait, Diana, Brown, Gina, Oates, Jacqueline, Braconi, Chiara, Valeri, Nicola, Sclafani, Francesco, Chau, Ian, Cunningham, David, Lampis, Andrea, Hahne, Jens Claus, Ghidini, Michele, Lote, Hazel, Zito, Domenico, Tabernero, Josep, Glimelius, Bengt, Cervantes, Andres, Begum, Ruwaida, De Castro, David Gonzalez, Wilson, Sanna Hulkki, Peckitt, Clare, Eltahir, Zakaria, Wotherspoon, Andrew, Tait, Diana, Brown, Gina, Oates, Jacqueline, Braconi, Chiara, and Valeri, Nicola

Abstract

Single nucleotide polymorphisms (SNPs) in microRNA genes have been associated with colorectal cancer (CRC) risk, survival and response to treatment. Conflicting results are available on the association between rs4919510, a SNP in mature miR-608 and clinical outcome in CRC. Here, we analyzed the association between rs4919510 and benefit from perioperative treatment in a randomised phase II trial of neoadjuvant Capecitabine and Oxaliplatin (CAPOX) followed by chemo-radiotherapy, surgery and adjuvant CAPOX +/- Cetuximab in high-risk locally advanced rectal cancer (LARC). A total of 155/164 (94.5%) patients were assessable. 95 (61.3%) were homozygous for CC, 55 (35.5%) heterozygous (CG) and 5 (3.2%) homozygous for GG. Median follow-up was 64.9 months. In the CAPOX arm the 5-year progression-free survival (PFS) and overall survival (OS) rates were 54.6% and 60.7% for CC and 82.0% and 82.1% for CG/GG, respectively (HR PFS 0.13, 95% CI: 0.12-0.83, P = 0.02; HR OS 0.38, 95% CI: 0.14-1.01, P = 0.05). In the CAPOX-C arm PFS and OS were 73.2 and 82.2%, respectively for CC carriers and 64.6 and 73.1% for CG/GG carriers (HR PFS 1.38, 95% CI: 0.61-3.13, P = 0.44; HR OS 1.34, 95% CI: 0.52-3.48, P = 0.55). An interaction was found between study treatment and rs4919510 genotype for both PFS (P = 0.02) and OS (P = 0.07). This is the first study investigating rs4919510 in LARC. The CC genotype appeared to be associated with worse prognosis compared to the CG/GG genotype in patients treated with chemotherapy and chemo-radiotherapy alone. Addition of Cetuximab to chemotherapy and chemo-radiotherapy in CC carriers appeared to improve clinical outcome.

Published
2016
Full Text
View/download PDF

17. Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients

Author

Sclafani, Francesco, primary, Chau, Ian, additional, Cunningham, David, additional, Lampis, Andrea, additional, Hahne, Jens Claus, additional, Ghidini, Michele, additional, Lote, Hazel, additional, Zito, Domenico, additional, Tabernero, Josep, additional, Glimelius, Bengt, additional, Cervantes, Andres, additional, Begum, Ruwaida, additional, De Castro, David Gonzalez, additional, Wilson, Sanna Hulkki, additional, Peckitt, Clare, additional, Eltahir, Zakaria, additional, Wotherspoon, Andrew, additional, Tait, Diana, additional, Brown, Gina, additional, Oates, Jacqueline, additional, Braconi, Chiara, additional, and Valeri, Nicola, additional

Published
2016
Full Text
View/download PDF

18. Correlation between mismatch repair deficiency (MMRd), microsatellite instability (MSI) and survival in MAGIC.

Author

Smyth, Elizabeth Catherine, primary, Wotherspoon, Andrew, additional, Peckitt, Clare, additional, Nankivell, Matthew Guy, additional, Eltahir, Zakaria, additional, Hulkki Wilson, Sanna, additional, Gonzalez de Castro, David, additional, Okines, Alicia Frances Clare, additional, Langley, Ruth E, additional, and Cunningham, David, additional

Published
2016
Full Text
View/download PDF

19. Comparison of the genetic profiles of primary colorectal cancers and their subsequent pulmonary metastases: Implications for targeted treatment.

Author

Moorcraft, Sing Yu, primary, Jones, Thomas, additional, Walker, Brian, additional, Ladas, George, additional, Kalaitzaki, Eleftheria, additional, Yuan, Lina, additional, Begum, Ruwaida, additional, Eltahir, Zakaria, additional, Wotherspoon, Andrew, additional, Montero Fernandez, Angeles, additional, Teixeira Mendes, Larissa Sena, additional, Gonzalez de Castro, David, additional, Hulkki Wilson, Sanna, additional, To, Ye Mong, additional, Bowcock, Anne, additional, and Chau, Ian, additional

Published
2016
Full Text
View/download PDF

20. Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC) : Results of the EXPERT-C trial.

Author

Sclafani, Francesco, Chau, Ian, Cunningham, David, Lampis, Andrea, Hahne, Jens, Braconi, Chiara, Peckitt, Clare, Gonzalez, David, Wilson, Sanna Hullki, Capdevila, Jaume, Glimelius, Bengt, Cervantes, Andres, Begum, Ruwaida, Brown, Gina, Tait, Diana M., Wotherspoon, Andrew, Eltahir, Zakaria, Yusuf-Adam, Sandra, Oates, Jacqueline Rose, Valeri, Nicola, Sclafani, Francesco, Chau, Ian, Cunningham, David, Lampis, Andrea, Hahne, Jens, Braconi, Chiara, Peckitt, Clare, Gonzalez, David, Wilson, Sanna Hullki, Capdevila, Jaume, Glimelius, Bengt, Cervantes, Andres, Begum, Ruwaida, Brown, Gina, Tait, Diana M., Wotherspoon, Andrew, Eltahir, Zakaria, Yusuf-Adam, Sandra, Oates, Jacqueline Rose, and Valeri, Nicola

Published
2015

21. Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.

Author

Khurum Khan, Rata, Mihaela, Cunningham, David, Dow-Mu Koh, Tunariu, Nina, Hahne, Jens C., Vlachogiannis, George, Hedayat, Somaieh, Marchetti, Silvia, Lampis, Andrea, Damavandi, Mahnaz Darvish, Lote, Hazel, Rana, Isma, Williams, Anja, Eccles, Suzanne A., Fontana, Elisa, Collins, David, Eltahir, Zakaria, Rao, Sheela, and Watkins, David

Subjects
COLON cancer treatment, REGORAFENIB, METASTASIS, FUNCTIONAL imaging sensors, ANTINEOPLASTIC agents
Published
2018
Full Text
View/download PDF

23. Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.

Author

Sclafani, Francesco, primary, Chau, Ian, additional, Cunningham, David, additional, Lampis, Andrea, additional, Hahne, Jens, additional, Braconi, Chiara, additional, Peckitt, Clare, additional, Gonzalez, David, additional, Hullki Wilson, Sanna, additional, Capdevila, Jaume, additional, Glimelius, Bengt, additional, Cervantes, Andres, additional, Begum, Ruwaida, additional, Brown, Gina, additional, Tait, Diana M., additional, Wotherspoon, Andrew, additional, Eltahir, Zakaria, additional, Yusuf-Adam, Sandra, additional, Oates, Jacqueline Rose, additional, and Valeri, Nicola, additional

Published
2015
Full Text
View/download PDF

24. Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study

Author

Khan, Khurum, Rata, Mihaela, Cunningham, David, Koh, Dow-Mu, Tunariu, Nina, Hahne, Jens C, Vlachogiannis, George, Hedayat, Somaieh, Marchetti, Silvia, Lampis, Andrea, Damavandi, Mahnaz Darvish, Lote, Hazel, Rana, Isma, Williams, Anja, Eccles, Suzanne A, Fontana, Elisa, Collins, David, Eltahir, Zakaria, Rao, Sheela, Watkins, David, Starling, Naureen, Thomas, Jan, Kalaitzaki, Eleftheria, Fotiadis, Nicos, Begum, Ruwaida, Bali, Maria, Rugge, Massimo, Temple, Eleanor, Fassan, Matteo, Chau, Ian, Braconi, Chiara, and Valeri, Nicola

Abstract

ObjectiveRegorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection.DesignPatients with RASmutant mCRC with biopsiable metastases were enrolled in this phase II trial. Dynamic contrast-enhanced (DCE) MRI was acquired pretreatment and at day 15 post-treatment. Median values of volume transfer constant (Ktrans), enhancing fraction (EF) and their product KEF (summarised median values of Ktrans× EF) were generated. Circulating tumour (ct) DNA was collected monthly until progressive disease and tested for clonal RASmutations by digital-droplet PCR. Tumour vasculature (CD-31) was scored by immunohistochemistry on 70 sequential tissue biopsies.ResultsTwenty-seven patients with paired DCE-MRI scans were analysed. Median KEF decrease was 58.2%. Of the 23 patients with outcome data, >70% drop in KEF (6/23) was associated with higher disease control rate (p=0.048) measured by RECIST V. 1.1 at 2 months, improved progression-free survival (PFS) (HR 0.16 (95% CI 0.04 to 0.72), p=0.02), 4-month PFS (66.7% vs 23.5%) and overall survival (OS) (HR 0.08 (95% CI 0.01 to 0.63), p=0.02). KEF drop correlated with CD-31 reduction in sequential tissue biopsies (p=0.04). RASmutant clones decay in ctDNA after 8 weeks of treatment was associated with better PFS (HR 0.21 (95% CI 0.06 to 0.71), p=0.01) and OS (HR 0.28 (95% CI 0.07–1.04), p=0.06).ConclusionsCombining DCE-MRI and ctDNA predicts duration of anti-angiogenic response to regorafenib and may improve patient management with potential health/economic implications.

Published
2018
Full Text
View/download PDF

25. Effect of dexamethasone administration on gonadalfertility functions in female albino rats.

Author

Mohammed, Fatima Yousif, Abdrabo, AbdElkarim Abobaker, Ahmed, Samia Mahdi, Abdulbadie, Ahmed, Eltahir, Zakaria, and Ismail, Amar Mohamed

Subjects
*OVARIAN follicle, *DEXAMETHASONE, *ALBINISM, *OVARIES, *INTERSTITIAL cells
Abstract

Introduction: dexamethasone is misused for skin whitening with broad effects on steroidogenesis and ovarian functions. Here in we investigated the impact of dexamethasone administration on gonadotropin Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH), prolactin, and ovarian tissues in albino rats. Methods: in the experimental study, 36 female albino rats weighting (140-162 g) were divided into three groups: control, normal dose received dexamethasone (8.3 µg/kg/day) and high dose (24.9 µg/kg/day), for 30 and 60 days. follicle stimulating hormone, luteinizing hormone, and prolactin (PRL) were measured. Histological ovarian sections were examined. Results: luteinizing hormone, follicle stimulating hormone and prolactin significantly increased (p-value < 0.05) following dexamethasone treatment compared to control. The ovary sections showed degenerative tissue with necrosis of the Graafian follicles, stromal fibrosis, and vacuolation of the interstitial cells. Conclusion: the study concludes that dexamethasone administration has a potentially adverse effect on gonadotropin, prolactin, and ovarian follicle cells in female albino rats. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results